We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Highly Sensitive Molecular Test Detects Cases of Tuberculosis

By LabMedica International staff writers
Posted on 28 Jun 2021
Tuberculosis (TB) is a bacterial infection spread through inhaling tiny droplets from the coughs or sneezes of an infected person. More...
It mainly affects the lungs, but it can affect any part of the body, including the tummy (abdomen), glands, bones and nervous system.

Tuberculosis (TB) is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. Most infections show no symptoms, in which case it is known as latent tuberculosis. About 10% of latent infections progress to active disease which, if left untreated, kills about half of those affected. Typical symptoms of active TB are a chronic cough with blood-containing mucus, fever, night sweats, and weight loss.

A team of Medical Scientists at the Barcelona Institute for Global Health (Barcelona, Spain) and their colleagues enrolled a total of 1,419 and 252 participants in the passive case finding (PCF) and (active case finding (ACF) cohorts. Single respiratory specimens from symptomatic adults accessing health care services PCF cohort, and from household and community close contacts ACF, were tested by smear microscopy, culture, sensitive molecular tests. Liquid and solid culture served as a composite reference standard. The team performed a field study to compare the performance of two molecular tests: 'Xpert MTB/RIF', developed in 2010, and its improved version, Xpert Ultra (Cepheid, Sunnyvale, CA, USA), developed three years ago and capable of detecting smaller amounts of DNA.

The investigators reported that for the PCF cohort, Ultra showed higher sensitivity than Xpert overall (0.95 (95% CI: 0.90, 0.98) versus 0.88 (0.82, 0.93) and among smear negative patients (0.63 (0.48, 0.76) and 0.84 (0.71, 0.93). Ultra's specificity was lower than Xpert's 0.98 (0.97, 0.99) versus 0.96 (0.95, 0.97). For ACF, sensitivities were the same (0.67 (95% CI: 0.22,0.96) for both tests), although Ultra detected a higher number of microbiologically confirmed samples than Xpert (12/252 (4.7%) versus 7/252 (2.7%). Conditional recategorization of trace results among previously treated participants maintained differences in specificity in the PCF cohort. Among the cohort of case contacts, the incidence was much lower, but even then the Ultra managed to detect cases that were not detected by Xpert or by liquid culture, likely because they had a very low burden of bacteria.

Alberto L. García-Basteiro, MD, PhD, an expert in tuberculosis and senior author of the study, said, “Most national programmes for TB control focus on detecting cases that attend the hospital, which tend to be more severe, but there are many cases with no or few symptoms that we are missing. If we want to achieve the End TB goals, we need to develop new diagnostic tools capable of identifying patients at earlier stages of the disease, with lower bacterial burdens, and that can be deployed at the patient's point of care.” The study was published on June 17, 2021 in the European Respiratory Journal.

Related Links:
Barcelona Institute for Global Health
Cepheid



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining Management Software
DakoLink
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.